Pure Global Cannabis’ Subsidiary Obtains Canadian License Amendment

Pure Global Cannabis (TSXV:PURE) announced its subsidiary PureSinse obtained approval for its Health Canada license to now include “the activity of possession of cannabis oil, resin, and relevant activities.”

As quoted in the press release:

PureSinse’s license under the ACMPR was amended August 24, 2018, allowing the company to source bulk psychoactive and non-psychoactive cannabis oils along with resins from national and international licensed producers that meet Pure Global’s high quality standards. The next step will be to receive Health Canada approvals to process, package, and sell cannabis oil-based products.

The Company anticipates that PureSinse will be granted a cannabis oils production and processing licence by the end of 2018 and subsequent oils sales licence in early 2019. Upon final licensing approval, PureSinse will have the ability to sell cannabis oil products to registered patients under the ACMPR, for adult legal use under the Cannabis Act, and for export purposes, along with its current dried medical cannabis products.

“This license is instrumental for PURE’s ability to initiate revenue generation from oils in the coming quarters, while driving our product innovation, amplifying our intellectual property portfolio, and propelling our research and development mandates for cannabis oils-based products. The Company will look to secure long-term supply agreements for bulk dried flower, extractable trim, and now for cannabis and cannabidiol (CBD) distillates, isolates, and extracts, for processing, packaging, and distribution,” said Pure Global President & CEO Malay Panchal.

Click here to read the full press release.

Source: www.newswire.ca